| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CANCER |
Centre de recherche en reproduction animale (D.B., N.B., A.K.G., J.S.) and Département de pathologie et microbiologie (M.D.), Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec, Canada J2S 7C6; and the Tenovus Center for Cancer Research (H.E.J.), Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, United Kingdom
Address all correspondence and requests for reprints to: Dr. Jean Sirois, Faculté de médecine vétérinaire, Université de Montréal, C. P. 5000, Saint-Hyacinthe, Québec, Canada J2S 7C6. E-mail: . siroisje{at}medvet.umontreal.ca
Induction of PG G/H synthase-2 (PGHS-2), a key rate-limiting enzyme in the PG biosynthetic pathway, has been implicated in prostatic adenocarcinomas in humans and dogs in vivo, but the molecular control of PGHS-2 expression in prostate cancer remains poorly understood. Using the dog model, the specific objectives of this study were to clone and characterize canine PGHS-2, and to study the regulation of its transcript, protein, and activity in a canine prostatic adenocarcinoma (CPA) cell line in vitro. The canine PGHS-2 cDNA was cloned by a combination of cDNA library screening and 5'-rapid amplification of cDNA ends, and shown to contain a 5'-untranslated region of 28 bp, an open reading frame of 1815 bp, and a 3'-untranslated region of 1655 bp. The open reading frame encodes a 604-amino acid protein that is 89% identical to the human homolog. The regulation of PGHS-2 protein and PGE2 synthesis was studied in CPA cells cultured in the absence or presence of graded doses of phorbol 12-myristate 13-acetate (PMA), TNF
, and lipopolysaccharides. Results from immunoblots, immunocytochemistry, and RIAs showed that PGHS-2 protein and PGE2 were present at low levels in control cells and were significantly induced after agonist treatment (P < 0.05), with PMA being the strongest inducer. Northern blot analyses also revealed a significant increase of PGHS-2 mRNA by PMA, TNF
, and lipopolysaccharides treatment (P < 0.05). Agonist-dependent induction of PGHS-2 mRNA was not dependent on new protein synthesis (coincubation with cycloheximide; 10 µg/ml) but was blocked by transcription inhibitor actinomycin D (5 µg/ml), suggesting that PGHS-2 acts an immediate early-response gene in prostatic epithelial cells. Thus, this study characterizes for the first time the structure of canine PGHS-2 and provides an in vitro model to unravel the molecular basis of PGHS-2 expression in prostatic adenocarcinomas.
This article has been cited by other articles:
![]() |
S. Boonsoda and P. Wanikiat Possible role of cyclooxygenase-2 inhibitors as anticancer agents Vet Rec., February 2, 2008; 162(5): 159 - 161. [Full Text] [PDF] |
||||
![]() |
M. Brunelle, E. A. Sartin, L. G. Wolfe, J. Sirois, and M. Dore Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines. Vet. Pathol., September 1, 2006; 43(5): 656 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Winkler, H. Murua Escobar, N. Eberle, N. Reimann-Berg, I. Nolte, and J. Bullerdiek Establishment of a Cell Line Derived from a Canine Prostate Carcinoma with a Highly Rearranged Karyotype J. Hered., November 1, 2005; 96(7): 782 - 785. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Beam, K. M. Rassnick, A. S. Moore, and S. P. McDonough An Immunohistochemical Study of Cyclooxygenase-2 Expression in Various Feline Neoplasms Vet. Pathol., September 1, 2003; 40(5): 496 - 500. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |